All three agents showed efficacy regarding glycaemic control and metabolic benefits; however, exenatide showed the greatest efficacy. ß-cell function improved in all treatment groups, hence early initiation of ß-cell-protective therapy may halt the decline in ß-cell function in type 2 diabetes (Journal of Internal Medicine)